RNA-directed cell fate reprogramming

Yen CHOO, Assoc Professor of Stem Cell Science and Regenerative Medicine

LEE KONG CHIAN SCHOOL OF MEDICINE

- Our lab is developing a platform technology to direct the conversion of one cell type into another, for biomedical applications e.g.
 - Conversion of pancreatic exocrine cells into new beta islet cells for diabetes therapy
 - Conversion of cochlear non-sensory cells into new hair cells to restore hearing loss
- We use bioinformatics and high throughput combinatorial screening to identify mRNA combinations for cell reprogramming
 - mRNAs encode transcription factors that reprogram gene regulatory networks
- mRNA as a vector for cell reprogramming therapies is highly advantageous
 - avoids sustained overexpression of transcription factors, leaves no genetic footprint
- We are interested to collaborate on:
 - Disease indications amenable to cell reprogramming as a therapeutic approach
 - Non-coding RNAs that control gene expression
 - mRNA modifications to enhance gene expression, suppress immunogenicity etc
 - improved mRNA delivery, particularly in vivo